A Comparison of Technegas and Xenon-133 Planar Lung Imaging in Subjects Referred for Ventilation Scintigraphy

Summary

Phase 3 within-subject non-inferiority trial of Technegas ventilation imaging compared to Xenon-133 (Xe-133) ventilation imaging to demonstrate the non-inferiority of Technegas compared to Xe-133 ventilation studies with respect to subject pulmonary ventilatory distribution. Subjects will undergo site-specific standard of care (SOC) Xe-133 imaging per medical needs followed by Technegas ventilation imaging per study protocol.

Timeline

Start

2017-09-01

Primary completion

2020-09-18

Completion

2020-11-23

Outcome

Met primary endpoint

Stopped: “Trial met primary efficacy endpoint target. No additional subjects necessary.”

registry NUMBER Blinded Reader 03: 76.2 (72.3 to 79.6) percentage of lung regions NCT03054870 ↗

registry NUMBER Blinded Reader 04: 70.7 (66.4 to 74.7) percentage of lung regions NCT03054870 ↗

registry NUMBER Blinded Reader 05: 80.1 (76.4 to 83.3) percentage of lung regions NCT03054870 ↗

registry analysis (non-inferiority test); Blinded Reader 03 vs Blinded Reader 04 vs Blinded Reader 05; p <0.0141 NCT03054870 ↗

Publications

• Parihar AS, Mhlanga JC, Royal HD, Siegel BA. Comparability of Quantifying Relative Lung Ventilation with Inhaled 99mTc-Technegas and 133Xe in Patients Undergoing Evaluation for Lung Transplantation. J Nucl Med. 2025 Jan 3;66(1):104-109. doi: 10.2967/jnumed.124.268801.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Technegas	Diagnostic / imaging agent	40.7 mbq	Inhaled
Subject	Xenon-133	Diagnostic / imaging agent	370 mbq	Inhaled
Subject	Xenon-133	Diagnostic / imaging agent	1110 mbq	Inhaled

Indications

No indication recorded.